Sensitivity and Agreement Analysis for PSMA PET/CT and mpMRI
| Type of analysis | All PCa | csPCa | Non-csPCa |
|---|---|---|---|
| Lesion-level, primary cohort (patient n = 100) | |||
| Lesions (n) | 156 | 132 | 24 |
| MRI+/PET+ | 101 (65%) | 101 (77%) | 0 |
| MRI−/PET− | 30 (19%) | 12 (9%) | 18 (75%) |
| MRI+/PET− | 8 (5%) | 5 (4%) | 3 (13%) |
| MRI−/PET+ | 17 (11%) | 14 (11%) | 3 (13%) |
| MRI sensitivity | 70% | 80% | 13% |
| PET sensitivity | 76% | 87% | 13% |
| Lesion-level, full cohort (patient n = 114) | |||
| Lesions (n) | 175 | 151 | 24 |
| MRI+/PET+ | 115 (66%) | 115 (76%) | 0 |
| MRI−/PET− | 32 (18%) | 14 (9%) | 18 (75%) |
| MRI+/PET− | 8 (5%) | 5 (3%) | 3 (13%) |
| MRI−/PET+ | 20 (11%) | 17 (11%) | 3 (13%) |
| MRI sensitivity | 70% | 79% | 13% |
| PET sensitivity | 77% | 87% | 13% |
| Patient-level, primary cohort (patient n = 100) | |||
| MRI+/PET+ | 92 (92%) | ||
| MRI−/PET− | 0 | ||
| MRI+/PET− | 2 (2%) | ||
| MRI−/PET+ | 6 (6%) | ||
| MRI sensitivity | 94% | ||
| PET sensitivity | 98% | ||
| Patient-level, full cohort (patient n = 114) | |||
| MRI+/PET+ | 105 (91%) | ||
| MRI−/PET− | 0 | ||
| MRI+/PET− | 2 (2%) | ||
| MRI−/PET+ | 7 (6%) | ||
| MRI sensitivity | 94% | ||
| PET sensitivity | 98% |